ImmunityBio, Inc. (IBRX) FY2025 10-K Annual Report
ImmunityBio, Inc. (IBRX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ImmunityBio, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Development and commercialization of biologic drugs, with focus on regulatory approvals and post-marketing requirements
- • New emphasis on commercialization efforts for approved product ANKTIVA and building sales, marketing, and distribution capabilities
- • Strategic shift toward handling complex FDA accelerated approval pathways and orphan drug exclusivity following 2026 Orphan Drug Act codification
- • Post-marketing commitments for ANKTIVA include QUILT-3.032 trial completion by end of 2029 and annual FDA reporting up to 4 years
- • Increased focus on cybersecurity risks and use of AI in business, highlighting vulnerabilities and operational disruption potentials
Management Discussion & Analysis
- • Revenue started from ANKTIVA sales since May 2024; no dollar amounts or YoY change disclosed
- • Operating expenses expected to increase substantially due to commercialization and R&D expansion; no margin % figures provided
- • No segment-specific performance data or best/worst performing segment disclosed
- • Cash and equivalents plus sales and potential equity offerings expected to fund operations for next 12 months; no buyback/dividend/capex details provided
- • Management highlights significant funding risks, need for additional capital to sustain operations, and regulatory/commercialization uncertainties impacting future outlook
Risk Factors
- • Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026
- • Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches
- • Supply vulnerability as company supports FDA Expanded Access Program for rBCG to address U.S. supply constraints
- • Competitive risk from CPI combination therapies in metastatic NSCLC with conditional SFDA approval and planned commercial launch in 60 days
- • Financial risk in rapid revenue growth: ANKTIVA sales $113M FY2025, 700% YoY increase, requiring scaling of 85-person EU sales force and global partnerships
ImmunityBio, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$113M
▲ +668.3% YoY
Net Income
-$351M
▲ +15.0% YoY
Operating Margin
-226.0%
▲ +210823bp YoY
Net Margin
-310.2%
▲ +249459bp YoY
ROE
70.2%
▼ -1434bp YoY
Total Assets
$502M
▲ +31.1% YoY
EPS (Diluted)
$-0.38
▲ +38.7% YoY
Operating Cash Flow
-$305M
▲ +22.1% YoY
Source: XBRL data from ImmunityBio, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ImmunityBio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.